Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OSE ImmunotherapeuticsORPOF 51 3-Year EBITDA Growth Rate is -25.70% as of Dec. 2025. GuruFocus rates ORPOF with a GF Score™ of 51/100 and a GF Value™ of $3.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,136 Biotechnology companies, OSE Immunotherapeutics ranks worse than 88.91% on this metric.
During the past 12 months, OSE Immunotherapeutics's average EBITDA Per Share Growth Rate was -177.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -25.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of OSE Immunotherapeutics was 8.60% per year. The lowest was -135.80% per year. And the median was -29.85% per year.
OSE Immunotherapeutics (OTCPK:ORPOF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
OSE Immunotherapeutics 3-Year EBITDA Growth Rate Related Terms
ORPOF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, OSE Immunotherapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OSE Immunotherapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where OSE Immunotherapeutics's 3-Year EBITDA Growth Rate falls into.
OSE Immunotherapeutics 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -25.70% mean?
OSE Immunotherapeutics (ORPOF) has a 3-Year EBITDA Growth Rate of -25.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for OSE Immunotherapeutics and its competitors. According to the industry distribution chart, OSE Immunotherapeutics ranks #1010 out of 1136 companies in the Biotechnology industry, placing it in the top 88.9%.
Is OSE Immunotherapeutics' 3-Year EBITDA Growth Rate too high?
OSE Immunotherapeutics' current 3-Year EBITDA Growth Rate is -25.70%. Based on the distribution chart, OSE Immunotherapeutics ranks #1010 out of 1136 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OSE Immunotherapeutics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OSE Immunotherapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OSE Immunotherapeutics ranks #1010 out of 1136 companies for 3-Year EBITDA Growth Rate. This places OSE Immunotherapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for OSE Immunotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OSE Immunotherapeutics's current 3-Year EBITDA Growth Rate is -25.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OSE Immunotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, OSE Immunotherapeutics (ORPOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.28, compared to a current price of $4.43 — trading 35.1% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -25.70%. OSE Immunotherapeutics' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For OSE Immunotherapeutics (ORPOF), the current 3-Year EBITDA Growth Rate is -25.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?
Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued.
The current stock price of $4.43 is trading 35.1% above its estimated GF Value™ of $3.28.
GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.
Key valuation signals for ORPOF:
3-Year EBITDA Growth Rate: -25.70%
GF Value™: $3.28 vs. price of $4.43 (35.1% above fair value)
No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
51GF Score
Get the complete analysis for ORPOF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORPOF has been successfully added to your 
